| |
|
| | |
 |
|
| About Syntonix | |
| Syntonix discovers and develops novel, long-acting, proprietary therapeutic products using the company’s proprietary Fc-fusion proteins and other engineered ligands which bind to specific Fc receptors. These technologies, including Syntonix’ drug delivery platform technology Transceptor®, harness the body’s natural pathways for protecting antibodies against premature destruction and for transporting antibodies across cell barriers such as those in the lungs and intestines. Syntonix focuses on using these technologies to create next generation treatments for devastating chronic diseases such as hematologic and autoimmune disorders. Syntonix develops selected products for specialty indications such as hemophilia. The company is headed by an experienced management team and has focused on using its proprietary technology to enhance existing drugs with proven safety, efficacy, and economic return. Syntonix is a wholly owned subsidiary of Biogen Idec. |
|
 |
|
 Home | About Syntonix | Science & Technology | News | Careers | Contact Us | Site Map Terms & Conditions of Use | Note Regarding Forward-Looking Statements | Privacy Policy © Biogen Idec - Biogen Idec is proud to be an Equal Opportunity Employer. |
